Please assess the completion status of the following clinical trial:

Trial Title: S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed bronchoalveolar carcinoma (BAC) or BAC variants such as adenocarcinoma with BAC features or BAC with invasive adenocarcinoma~  * Cytology specimens, such as bronchial brushings, washings, or fine needle aspiration specimens alone are not acceptable for diagnosis~* Stage IV disease OR selected stage IIIB (T4 \[secondary to malignant pleural effusion only\], any N, M0) disease~* Incompletely resected or unresectable disease~* Pleural effusions, ascites, or laboratory parameters cannot be only evidence of disease~* Measurable disease or nonmeasurable disease documented by CT scan~* No known brain metastases~PATIENT CHARACTERISTICS:~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* SGOT and SGPT ≤ 2.5 times ULN ( ≤ 5 times ULN if due to liver metastases)~* Alkaline phosphatase ≤ 2.5 times ULN ( ≤ 5 times ULN if due to bone metastases)~* Creatinine clearance ≥ 45 mL/min OR creatinine ≤ 1.5 times ULN~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 75,000/mm³~* Zubrod 0-2~* No history of allergic reaction to compounds of similar chemical or biological composition as pemetrexed disodium~* Must provide smoking history~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Able to swallow pills~PRIOR CONCURRENT THERAPY:~* No more than 2 prior systemic therapies (including epidermal growth factor receptor inhibitor)~* At least 28 days since prior systemic therapy~* Patients treated with prior erlotinib or gefitinib must have shown progression since treatment~* No prior pemetrexed disodium~* At least 28 days since prior radiotherapy and recovered~  * Must have measurable or nonmeasurable disease outside previously irradiated area or a new lesion within previously irradiated area~* At least 14 days since prior palliative radiotherapy and recovered~* At least 28 days since prior thoracic or major surgery and recovered~* No concurrent surgery~* No other concurrent therapy (hormonal, biologic or radiotherapy) for this disease~* No concurrent antiretroviral therapy~* Patients should discontinue non-steroidal anti-inflammatory drugs (NSAIDs) with longer half lives (etodolac, ketordac, sulindac, naproxen, naproxen sodium, oxaprozin, nabumetone, diflunisal, salsalate, celecoxib, rofecoxib, valdecoxib, meloxicam, piroxicam) at least 5 days before and for 2 days following pemetrexed treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed (Type: EXPERIMENTAL): pemetrexed

Based on this trial design, predict the completion outcome and termination type (if applicable).